Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Dimerix Limited ( (AU:DXB) ) is now available.
Dimerix Limited announced that its CEO, Dr. Nina Webster, will present at the Canaccord Drug & Device Conference 2025, highlighting the status of their Phase 3 global clinical trial for FSGS kidney disease and commercial partnering efforts. This presentation underscores Dimerix’s commitment to advancing DMX-200, a promising treatment for FSGS, a rare kidney disorder with limited treatment options, potentially enhancing their market positioning and offering hope for patients with unmet medical needs.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.46 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
More about Dimerix Limited
Dimerix Limited is a clinical-stage biopharmaceutical company focused on developing innovative therapies for inflammatory diseases, including kidney and respiratory diseases. Their primary product candidates include DMX-200 for Focal Segmental Glomerulosclerosis (FSGS) kidney disease and DMX-700 for respiratory disease, both identified using their proprietary Receptor Heteromer Investigation Technology (Receptor-HIT).
Average Trading Volume: 1,514,950
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$309.1M
Learn more about DXB stock on TipRanks’ Stock Analysis page.